KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Gross Profit (2016 - 2025)

Historic Gross Profit for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $373.0 million.

  • Halozyme Therapeutics' Gross Profit rose 4572.87% to $373.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 3644.44%. This contributed to the annual value of $1.2 billion for FY2025, which is 3644.44% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Gross Profit of $373.0 million as of Q4 2025, which was up 4572.87% from $299.0 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Gross Profit high stood at $373.0 million for Q4 2025, and its period low was $70.8 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $164.6 million (2022), whereas its average is $177.2 million.
  • The largest annual percentage gain for Halozyme Therapeutics' Gross Profit in the last 5 years was 26184.9% (2021), contrasted with its biggest fall of 1573.39% (2021).
  • Halozyme Therapeutics' Gross Profit (Quarter) stood at $80.4 million in 2021, then soared by 73.32% to $139.4 million in 2022, then increased by 27.53% to $177.7 million in 2023, then skyrocketed by 44.0% to $256.0 million in 2024, then soared by 45.73% to $373.0 million in 2025.
  • Its Gross Profit stands at $373.0 million for Q4 2025, versus $299.0 million for Q3 2025 and $279.4 million for Q2 2025.